Aurora Cannabis Announces Fiscal 2026 Fourth Quarter and Full Year Results

Aurora Cannabis Inc. reported its financial and operational results for the fourth quarter and fiscal year 2026. The company achieved record annual global medical cannabis net revenue of $288.6 million, an 18% year-over-year increase, and record annual Adjusted EBITDA of $53.8 million, a 32% year-over-year increase. Key highlights for Q4 2026 include a 10% increase in total net revenue to $84.8 million, driven by a 14% growth in the global medical cannabis business. The company also completed the acquisition of Safari Flower Company, an EU-GMP certified manufacturer. For the full fiscal year 2027, Aurora anticipates a decline in total net revenue, aligning with 2025 levels, due to changes in Canadian medical cannabis pricing, partially offset by international growth. Adjusted EBITDA is expected to be lower annually compared to the prior fiscal year. The company maintained a strong balance sheet with approximately $164.7 million in cash and no debt.